Follow The Filings

DYN Dyne Therapeutics Inc.

Health Care, filed as DYNE THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 Owner
  • Max 5.1%
  • $37M
  • 1 exit 1 small

In 2026 Q2 Farallon Capital Management sold out of Dyne Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 5.1% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors Reduce 5.1%

Who owns DYN

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 5.1% Small trim −0.3% 1,647,521 $37M History
Farallon Capital Management exited 2026 Q2 Last 2026 Q1 <0.01% Exit 0.00% 10,000 $181K History

1 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by DYN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All DYN insider trades
  • $315K bought by 1 insider
  • None no sales outside a trading plan
  • $168M sold by 2 insiders under 10b5-1 plans
  1. Brian S Posner Director
    Buy
    $40K 2,500 shares at $16.00 +10% to stake
    Traded Oct 2 Filed Oct 6
    ↗
  2. Jason P Rhodes Director
    Planned sale
    $65.2M 2,586,928 shares at $25.20 86% of stake
    Traded Aug 13–14 Filed Aug 17
    ↗
  3. Dirk Kersten Director
    Planned sale
    $6.7M 261,460 shares at $25.51 6.8% of stake
    Traded Jul 27 Filed Jul 29
    ↗
  4. Jason P Rhodes Director
    Planned sale
    $17.9M 777,451 shares at $22.97 100% of stake
    Traded Jul 6–7 Filed Jul 8
    ↗
  5. Jason P Rhodes Director
    Planned sale
    $10.7M 504,695 shares at $21.23 34% of stake
    Traded Jun 26–29 Filed Jun 30
    ↗
  6. Jason P Rhodes Director
    Planned sale
    $5.6M 267,760 shares at $21.09 20% of stake
    Traded Jun 23–25 Filed Jun 26
    ↗
  7. Dirk Kersten Director
    Planned sale
    $5.5M 263,962 shares at $20.70 6.4% of stake
    Traded Jun 22–23 Filed Jun 24
    ↗
  8. Dirk Kersten Director
    Planned sale
    $1.7M 84,355 shares at $20.10 2% of stake
    Traded Jun 17–18 Filed Jun 22
    ↗
  9. Brian S Posner Director
    Buy
    $34K 2,000 shares at $16.94 +8.9% to stake
    Traded Jun 8 Filed Jun 9
    ↗
  10. Brian S Posner Director
    Buy
    $44K 2,500 shares at $17.48 +13% to stake
    Traded Jun 3 Filed Jun 5
    ↗
  11. Brian S Posner Director
    Buy
    $36K 2,000 shares at $18.21 +11% to stake
    Traded May 26 Filed May 28
    ↗
  12. Brian S Posner Director
    Buy
    $43K 2,500 shares at $17.12 +16% to stake
    Traded May 20 Filed May 22
    ↗
  13. Jason P Rhodes Director
    Planned sale
    $1.9M 106,723 shares at $18.14 8.6% of stake
    Traded May 4–6 Filed May 6
    ↗
  14. Jason P Rhodes Director
    Planned sale
    $4.2M 227,337 shares at $18.38 16% of stake
    Traded Apr 28 Filed Apr 30
    ↗
  15. Jason P Rhodes Director
    Planned sale
    $7.1M 384,549 shares at $18.47 24% of stake
    Traded Apr 23–27 Filed Apr 27
    ↗

Also filed in the last 12 months, not counted as buying or selling: 24 sales to cover taxes, 5 stock grants, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 13 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
8-K 8.01 Filing Doc
8-K 5.02 Filing Doc
8-K 1.01,2.03 Filing Doc

Source: SEC EDGAR submissions, updated 10 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$235.94M -$317.42M -$446.21M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.129B $0.659B $1.13B
Total non-current assets * $35.71M $31.96M $31.2M
Total assets $0.165B $0.691B $1.19B
Total current liabilities $51.1M $42.26M $50.62M
Total non-current liabilities * $22.7M $19.14M $164.2M
Total equity $91.29M $629.84M $972.13M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$188.16M -$292.37M -$403.21M
Cash from investing $83.31M -$204.08M -$28.75M
Cash from financing $54.32M $809.9M $890.31M
Net change in cash -$50.52M $313.45M $458.35M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.